NewsBenzingaTonix Pharmaceuticals Q3 BPA de $(2,89) no alcanza la estimación de $(2,31), ventas de $17,200 millones superan la estimación de $16,717 millones Tonix Pharmaceuticals Q3 BPA de $(2,89) no alcanza la estimación de $(2,31), ventas de $17,200 millones superan la estimación de $16,717 millones Benzinga 2026.11.09 12:03 (GMT+0) Open on Benzinga Other news Wolfe Research Initiates Coverage On Monster Beverage with Outperform Rating Druckenmiller Buys Miners, Warns '27 Could Be 'Disappointing' Wolfe Research Initiates Coverage On Keurig Dr Pepper with Outperform Rating, Announces Price Target of $42 Wolfe Research Initiates Coverage On PepsiCo with Peer Perform Rating BTIG Reiterates Neutral on FuboTVto Neutral Bitcoin Erases Summer Rally as ETF Outflows Persist
Wolfe Research Initiates Coverage On Keurig Dr Pepper with Outperform Rating, Announces Price Target of $42